Inactive Instrument

Immunodiagnostic Systems Holdings PLC

Equities

IDH

GB00B01YZ052

Medical Equipment, Supplies & Distribution

Immunodiagnostic Systems Holdings PLC Provides Trading Update for the Financial Year Ended 31 March 2017

April 21, 2017 at 02:00 am EDT

Immunodiagnostic Systems Holdings PLC provided trading update for the financial year ended 31 March 2017. For the year, total group revenue is expected to be approximately £40 million, an increase of around 4% compared to the previous year.

Latest news about Immunodiagnostic Systems Holdings PLC

Immunodiagnostic Systems Holdings PLC's Equity Buyback announced on June 21, 2017, has expired.	21-07-11	CI
PerkinElmer (UK) Holdings Limited completed the acquisition of Immunodiagnostic Systems Holdings PLC from a group of investors.	21-07-11	CI
DiaSorin S p A : Launches Antigen Test To Detect COVID-19 Infection	21-05-25	MT
Immunodiagnostic : Agrees To $155 Million Takeover Bid From PerkinElmer	21-05-17	MT
PerkinElmer : to Acquire UK-Based Diagnostic Company Immunodiagnostic Systems	21-05-17	MT
PerkinElmer (UK) Holdings Limited entered into an agreement to acquire Immunodiagnostic Systems Holdings PLC from a group of investors for approximately £110 million.	21-05-16	CI
Immunodiagnostic : Earnings Flash (IDH.L) IMMUNODIAGNOSTIC SYSTEMS Reports H2 Revenue GBP12.2M	21-04-16	MT
Immunodiagnostic Systems Holdings PLC Reports Unaudited Group Revenues for the Financial Year Ended March 31, 2021	21-04-16	CI
Immunodiagnostic Systems Holdings PLC Provides Unaudited Revenue Guidance for the Second Half for the Fiscal Year Ended March 31, 2021	21-04-16	CI
Immunodiagnostic : COVID-19 Test Authorized for Emergency Use in US	21-03-29	MT
Update: Immunodiagnostic Systems Soars 34% on Launch of COVID-19 Antigen Rapid Test Kits	20-11-27	MT
Immunodiagnostic : Starts Selling COVID-19 Antigen Rapid Test Kits	20-11-27	MT
Immunodiagnostic Systems Holdings PLC Announces Two SARS-CoV-2 Antigen Rapid Test Kits Are Available for Sale in the UK	20-11-27	CI
Immunodiagnostic Systems Holdings PLC Reports Unaudited Group Financial Results for the Six Months Ended 30 September 2020	20-11-20	CI
Tranche Update on Immunodiagnostic Systems Holdings PLC's Equity Buyback Plan announced on June 21, 2017.	20-11-20	CI
Immunodiagnostic Systems Holdings plc Provides Unaudited Group Revenues for the Months Ended 30 September 2020	20-10-23	CI
Immunodiagnostic Systems Holdings plc Launches New Range of Automated Therapeutic Drug Monitoring Assays for Use on the IDS-iSYS	20-09-16	CI
Immunodiagnostic Systems Holdings plc to Provide Contract Manufacturing Services to the Binding Site	20-08-27	CI
Immunodiagnostic Systems Holdings PLC Announces Automated IgM Assay to Detect SARS-CoV-2	20-08-13	CI
Immunodiagnostic Systems Holdings plc Launches Automated IDS Cortisol Assay	20-08-04	CI
No Bars, No Problem for Boston Beer -- Earnings at a Glance	20-07-23	DJ
Drop in Demand Hits Car Makers -- Earnings at a Glance	20-07-23	DJ
Immunodiagnostic Systems Holdings PLC Announces Revenue Results for the First Quarter Ended June 30, 2020	20-07-23	CI
Immunodiagnostic Systems Holdings PLC Provides Revenue Guidance for the Second Quarter 2021	20-07-23	CI
Immunodiagnostic Systems Holdings PLC Announces Launch of assay to Detect SARS-CoV-2 Antibodies	20-06-30	CI

Chart Immunodiagnostic Systems Holdings PLC

Duration

Period

Chart Immunodiagnostic Systems Holdings PLC

More charts

Company Profile

Immunodiagnostic Systems Holdings PLC is a specialist in vitro diagnostic solution provider to the clinical laboratory market. The Company develops, manufactures and markets immunoassays and automated immunoanalyser technologies. It operates through three business segments: Automated IVD, Manual IVD, and Licensing & Technology. The automated IVD business consists of 25-OH Vitamin D, specialties and instrument sales. The automated IVD business also consists of the sale or placement of its IDS-iSYS instrument, in addition to selling automated assays and consumables for use in these instruments. The Manual IVD business sells manual assays, radio immunoassays (RIA) and ELISA kits (EIA) to labs. Its assay development is focused in the clinical areas, such as calcium metabolism, bone metabolism, chronic kidney disease, hypertension, fertility and growth. Its subsidiaries include Immunodiagnostic Systems Limited, Immunodiagnostic Systems Nordic A/S and Immunodiagnostic Systems France SAS.

Sector

Medical Equipment, Supplies & Distribution

More about the company

Sector Diagnostic & Testing Substances

	1st Jan change	Capi.
BIOMÉRIEUX	-1.29%	12.64B
SHENZHEN NEW INDUSTRIES BIOMEDICAL ENGINEERING CO., LTD.	-0.47%	8.46B
LANTHEUS HOLDINGS, INC.	+22.61%	5.27B
AUTOBIO DIAGNOSTICS CO., LTD.	-2.03%	4.49B
10X GENOMICS, INC.	-53.56%	3.11B
ANDON HEALTH CO., LTD.	+19.30%	2.87B
MYRIAD GENETICS, INC.	+33.07%	2.31B
VITROLIFE AB	-8.42%	2.23B
GUANGZHOU WONDFO BIOTECH CO.,LTD	-3.55%	1.89B

Diagnostic & Testing Substances